Legato Capital Management’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
Legato Capital Management's NPCE Position: Q3 2026 in Review
Legato Capital Management reduced its Neuropace (NPCE) stake by 11% in Q3 2026, selling an estimated $114K and leaving 62,633 shares worth $862K. The position accounts for 0.08% of the portfolio, ranked #393.
Legato Capital Management first reported a position in NPCE in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.12M in Q2 2026. 105 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.
- Legato Capital Management held 62,633 shares of Neuropace worth $862K as of Q3 2026.
- Legato Capital Management sold 7,701 Neuropace shares in Q3 2026, an estimated $114K.
- Neuropace made up 0.08% of Legato Capital Management's portfolio in Q3 2026, its #393 holding.
- Legato Capital Management first reported a position in Neuropace in Q1 2025 and has held it in 7 quarters since.
- Legato Capital Management's Neuropace position peaked at $1.12M in Q2 2026.
- 105 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.
Based on Legato Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.